Discovery of heterocyclic replacements for the coumarin core of anti-tubercular FadD32 inhibitors
Chao Fang(Nanjing Medical University), Deborah T. Hung(Broad Institute), Robert H. Bates(Martha's Vineyard Hospital), Katie K. Lee(Broad Institute), James Gomez(Broad Institute), Laura Guijarro-López(GlaxoSmithKline (Spain)), Stewart L. Fisher(C4 Therapeutics (United States)), Zuozhong Peng(WuXi AppTec (China)), Eva María López-Román(GlaxoSmithKline (Spain)), Brian K. Hubbard(Broad Institute), Raymond Nietupski(Broad Institute), Michael H. Serrano‐Wu(Broad Institute), David Barros-Aguirre(GlaxoSmithKline (Spain)), Yunxing Yin(WuXi AppTec (China)), Raquel Fernández Menéndez(GlaxoSmithKline (Spain))
Cited by 19
Related Papers
Nucleic acid detection with CRISPR-Cas13a/C2c2
|Science|2017|3.9k
Definitions and guidelines for research on antibiotic persistence
|Nature Reviews Microbiology|2019|1.3k
Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect
|Nature|2010|940
Detection of SARS-CoV-2 with SHERLOCK One-Pot Testing
|New England Journal of Medicine|2020|801